U.S. CDMRP – Amyotrophic Lateral Sclerosis Research Program
Event details
| Date | 06.06.2025 |
| Category | Call for proposal |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2025 Amyotrophic Lateral Sclerosis Research Program (ALSRP) Awards. Several award programs are available:
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline: 06 June 2025, 5:00 p.m. Eastern time
Full Application Deadline: 27 August 2025, 11:59 p.m Eastern Time
Further information:
- The Clinical Outcomes and Biomarkers Award supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Applications must address at least one of the focus areas listed here.
- The Pilot Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or symptom management of ALS. Proposed projects may range from phase 1 to small-scale phase 2 trials. Applications must address at least one of the focus areas listed here.
- The Therapeutic Development Award supports research ranging from preclinical validation of therapeutic leads through FDA IND-enabling studies. The proposed studies are expected to be empirical in nature and product driven. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints, and pathophysiology. Candidate therapeutics that already have been granted an IND are not appropriate for the TDA.
- The Therapeutic Idea Award supports new, innovative, high-risk, high-gain ideas aimed at Amyotrophic Lateral Sclerosis (ALS) drug or therapy discovery. The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation
- Clinical Outcomes and Biomarkers Award: max. $750,000
- Pilot Clinical Trial Award: max. $2M
- Therapeutic Development Award: max. $1.5M
- Therapeutic Idea Award: max. $600,000
- Clinical Outcomes and Biomarkers Award: 3 years
- Pilot Clinical Trial Award: 3 years
- Therapeutic Development Award: 3 years
- Therapeutic Idea Award: 2 years
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline: 06 June 2025, 5:00 p.m. Eastern time
Full Application Deadline: 27 August 2025, 11:59 p.m Eastern Time
Further information:
- To find the full program announcements and to start your pre-application see here
- A useful summary of each call can be found here
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
- Grants.gov Funding Opportunity Numbers:
- Clinical Outcomes and Biomarkers Award: HT942525ALSRPCOBA
- Pilot Clinical Trial Award: HT942525ALSRPPCTA
- Therapeutic Development Award : HT942525ALSRPTDA
- Therapeutic Idea Award: HT942525ALSRPTIA
Practical information
- General public
- Free
Contact
- research@epfl.ch